Pharmaceuticals
News Category
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Platform
VERAXA Biotech AG appoints Christoph Erkel as CSO to lead development of its BiTAC platform for solid tumor cancer therapies, signaling a strategic pu...
NanoViricides Raises Approximately $3.8 Million in Registered Direct Offering
NanoViricides secures $3.8 million from a registered direct offering to advance its broad-spectrum antiviral drug candidate NV-387 and other programs.
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Platform
VERAXA Biotech AG has appointed Christoph Erkel as CSO to lead the development of its BiTAC platform for solid tumor cancer therapies, leveraging his ...
VERAXA Biotech Advances BiTAC-TCE Program with Positive Regulatory Feedback from German PEI
VERAXA Biotech has received Scientific Advice from Germany's Paul-Ehrlich-Institute supporting its BiTAC-TCE development, reducing uncertainty before ...
VERAXA Biotech Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform, Advancing Toward Clinical Development
VERAXA Biotech AG announced positive regulatory feedback from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE platform, providing clarity on develo...
Siegfried Appoints Eduardo Montanha as Chief Operating Officer to Drive Integrated Operations Strategy
Siegfried's appointment of Eduardo Montanha as COO, effective September 1, 2026, supports its strategy to offer integrated end-to-end solutions across...
NextPlat Corp Expands PharmcoRx With Planned Florida Pharmacy Acquisition
NextPlat Corp agrees to acquire an independent pharmacy near Pensacola, Florida, for $1.5 million to expand its PharmcoRx retail footprint into an und...
Onco-Innovations Completes Reference Standard Program for Lead Cancer Drug
Onco-Innovations announced the successful completion of an analytical reference standard program for its lead oncology candidate ONC010, a key step to...
VERAXA Biotech Advances Lead BiTAC T-Cell Engager Program with Cell Line Development Partnership
VERAXA Biotech AG has initiated cell line development for its lead BiTAC T-cell engager program by partnering with ATUM, a key step toward IND/CTA-ena...
Sustained Release Polymers Market Set to Reach USD 7.8 Billion by 2036, Driven by Chronic Disease Management and Drug Delivery Innovation
The global sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036, fueled by rising chronic di...
VERAXA Biotech Advances BiTAC Pipeline and Partnering Strategy in First Half of 2026
VERAXA Biotech AG updated on its BiTAC platform progress, with four T-cell engager programs and two bispecific ADC programs, while seeking partnership...
VERAXA Biotech Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
VERAXA Biotech has started cell line development for its lead BiTAC T-cell engager program, aiming to improve tumor selectivity and reduce off-tumor t...
VERAXA Biotech AG’s Antibody Platform Positioned for Value Creation Amid Strong Sector Deal Activity
The article highlights how VERAXA Biotech AG, with its next-generation antibody platform, is poised to benefit from the sustained high level of strate...
Ace Therapeutics Unveils Comprehensive Preclinical Pain Research Platform for Analgesic Drug Development
Ace Therapeutics announces a full-spectrum preclinical analgesic drug development service with diverse in vivo pain models and integrated research cap...
Medios AG Closes Aschaffenburg Facility to Optimize Manufacturing Network Amid Margin Pressure
Medios AG is closing its Aschaffenburg facility and consolidating patient-specific manufacturing to improve profitability, affecting 32 employees, as ...
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Trial on Track
Helus Pharma announced fiscal 2026 financial results and provided updates on its clinical pipeline, with its lead candidate HLP003 for major depressiv...
Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated co...
Knight Therapeutics Repays $60 Million Credit Facility Used for Paladin Acquisition
Knight Therapeutics has fully repaid its $60 million revolving credit facility drawn to finance the Paladin acquisition, using operational cash flow, ...
Voyageur Pharmaceuticals Evaluates Three U.S. Sites for Integrated Iodine and Barium Contrast Media Manufacturing Facility
Voyageur Pharmaceuticals is analyzing three potential U.S. locations for its vertically integrated contrast media plant, aiming to secure the best inc...
Earth Science Tech Inc. (ETST) Strengthens Position in Telemedicine and Pharmacy Ecosystem
Earth Science Tech Inc. has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy platform, emphasizing ...
Voyageur Pharmaceuticals Submits Multi-Year Permit Application for Frances Creek Barite Project
Voyageur Pharmaceuticals has submitted a Multi-Year Area-Based Notice of Work application to advance the Frances Creek barite project, including test ...
Voyageur Pharmaceuticals Closes $5 Million Private Placement for Barium and Iodine Contrast Development
Voyageur Pharmaceuticals raised $5,005,278.32 through a non-brokered private placement to fund FDA licensing for its barium contrast products, regulat...
Kairos Pharma Updates on Pipeline Expansion and Clinical Milestones in Mid-Year 2026 Shareholder Update
Kairos Pharma announced plans to acquire rights to CL-741, a Phase 1-ready oral c-MET inhibitor, and highlighted progress in its oncology pipeline inc...
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Opportunities on BioMedWire Podcast
Quantum BioPharma's lead drug candidate Lucid-MS targets nerve damage in multiple sclerosis, addressing an unmet need, while its commercial product un...
Quantum BioPharma Advances Multiple Sclerosis Program With Differentiated Approach
Quantum BioPharma Ltd. (NASDAQ: QNTM) advances a clinical-stage multiple sclerosis program targeting demyelination, differentiating from immune-modula...
Redwood AI Corp. Gains DTC Eligibility and Engages IBN for Investor Awareness Campaign
Redwood AI Corp. announces DTC eligibility to simplify U.S. trading and liquidity, and hires IBN for a $114,000 investor awareness campaign through Se...
Carmed Pharmaceuticals Gains CityBiz Feature as U.S. Expansion Accelerates
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol formulations, is featured in CityBiz as it expands into the U.S....
Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit to Accelerate AI-Driven Antibody Discovery
Sino Biological's new XPressMAX™ Cell-Free Protein Synthesis Kit enables ultra-fast protein and antibody synthesis in just 3 hours, supporting AI-powe...
NanoViricides Advances NV-387 Toward Phase II Trials for MPox in DRC
NanoViricides reported progress in its quarterly filing, highlighting regulatory approval for Phase II MPox trials in the DRC and FDA orphan drug desi...
NanoViricides Prices $2 Million Registered Direct Offering
NanoViricides announced a $2 million registered direct offering to an institutional investor, providing capital for its broad-spectrum antiviral drug ...
Lantern Pharma Raises $4.4 Million in Registered Direct Offering, Signaling Continued Growth in Precision Oncology
Lantern Pharma closed a $4.4 million registered direct offering, using proceeds to advance its AI-driven precision oncology pipeline and expanding its...
Tonix Pharmaceuticals to Present at Two Major Investor Conferences in May
Tonix Pharmaceuticals will showcase its commercial and pipeline progress at the RBC Capital Markets Global Healthcare Conference and A.G.P.’s Annual V...
Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery
Lantern Pharma's expansion of its predictBBB platform into a Large Quantitative Model enhances drug discovery by providing real-time, web-based molecu...
LIXTE Biotechnology’s LB-100 Poised to Transform Cancer Treatment by Enhancing Existing Therapies
LIXTE Biotechnology’s first-in-class PP2A inhibitor LB-100 is advancing through clinical trials for solid tumors with high unmet need, offering a nove...
Soligenix Showcased for Platform-Based Drug Development Strategy
Soligenix leverages its synthetic hypericin platform across multiple dermatologic indications, demonstrating how platform technology can streamline dr...
PolyPeptide Shareholders Approve All Board Proposals at 2026 Annual General Meeting
The shareholders of PolyPeptide Group AG approved all board proposals, including re-election of directors and auditors, at the company's fifth annual ...
LIXTE Biotechnology Holdings Files 2025 Form 10-K, Detailing Transformational Year of Clinical and Strategic Progress
LIXTE Biotechnology Holdings filed its 2025 Form 10-K, highlighting a year of leadership changes, clinical advancement of LB-100, the acquisition of L...
LIXTE Biotechnology's LB-100: The Only Clinical-Stage PP2A Inhibitor Poised to Transform Cancer Treatment
LIXTE Biotechnology holds the world's only clinical-stage PP2A inhibitor, LB-100, which enhances sensitivity to immunotherapy and chemotherapy while d...
Lonza Nominates Stephen Fry as Independent Board Member
Lonza nominates Stephen Fry, former Eli Lilly executive, to its Board, aiming to enhance performance culture and organizational transformation, with e...
Voyageur Pharmaceuticals Advances Barium and Iodine Contrast Media Projects with Strategic Feasibility Studies
Voyageur Pharmaceuticals is progressing its vertically integrated barium and iodine contrast media projects, completing bankable feasibility studies t...
Soligenix Secures EMA Positive Opinion for Dusquetide in Behçet's Disease, Unlocking European Development Incentives
Soligenix receives positive EMA opinion for orphan drug designation of dusquetide in Behçet's disease, providing market exclusivity and development in...
Quoin's NETHERTON NOW Campaign Surpasses 2 Million Video Views, Amplifying Awareness of Netherton Syndrome
Quoin Pharmaceuticals' NETHERTON NOW campaign has generated 2 million video views and 24 million impressions, highlighting the growing global awarenes...
Oncotelic Therapeutics Featured in BioMedWire Editorial on Late-Stage Biotech M&A Trends
Oncotelic Therapeutics is highlighted in a BioMedWire editorial examining how biotech M&A is increasingly targeting late-stage, de-risked assets, posi...
Helus Pharma Reports Positive Phase 2a SPL026 Data Published in Nature Medicine
Helus Pharma announced that its Phase 2a trial of SPL026 for major depressive disorder showed significant symptom reduction and was published in Natur...
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
BioVaxys announced positive Phase 2 results for MVP-S combined with pembrolizumab and low-dose cyclophosphamide in metastatic bladder cancer, showing ...
Quantumzyme Corp. Reports 2025 Progress and Sets 2026 Strategic Goals, Including AI Integration and Name Change
Quantumzyme Corp. outlines its 2025 achievements in enzyme R&D and AI integration, and announces a proposed name change to Quantum Genesis AI Corp. as...
Creative Biolabs Upgrades Biosimilar Development and CDMO Platform to Enhance Physicochemical and Biological Characterization
Creative Biolabs announces an upgrade to its end-to-end biosimilar development and CDMO platform, expanding capabilities in physicochemical characteri...
Protheragen Delivers Comprehensive Drug Analysis Solutions Integrating Stability, Impurity, and Chemical-Physical Testing
Protheragen's integrated drug analysis services, including stability studies, impurity testing, and chemical-physical tests, support pharmaceutical de...